Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson's Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up
Por:
Diego, SG, Teresa, DD, Cores, C, Canfield, H, Paz Gonzalez, JM, Miro, CM, Aymerich, LV, Suarez, E, Jesus, S, Aguilar, M, Pastor, P, Planellas, L, Cosgaya, M, Caldentey, JG, Caballol, N, Legarda, I, Hernandez-Vara, J, Cabo, I, Manzanares, LL, Aramburu, IG, Avila Rivera, MA, Catalan, MJ, Nogueira, V, Puente, V, Dotor, J, Borrue, C, Solano, B, Alvarez Sauco, M, Vela, L, Escalante, S, Cubo, E, Carrillo, F, Martinez Castrillo, JC, Alonso, PS, Alonso, G, Ariztegui, NL, Gaston, I, Kulisevsky, J, Blazquez, M, Seijo, M, Ruiz Martinez, J, Valero, C, Kurtis, M, de Fabregues, O, Ardura, J, Alonso, R, Ordas, C, Diaz, LML, McAfee, D, Martinez-Martin, P, Mir, P, COPPADIS Study Group
Publicada:
1 jul 2021
Resumen:
Background and Objective: Non-motor symptoms (NMS) progress in different ways between Parkinson's disease (PD) patients. The aim of the present study was to (1) analyze the change in global NMS burden in a PD cohort after a 2-year follow-up, (2) to compare the changes with a control group, and (3) to identify predictors of global NMS burden progression in the PD group. Material and Methods: PD patients and controls, recruited from 35 centers of Spain from the COPPADIS cohort from January 2016 to November 2017, were followed-up with after 2 years. The Non-Motor Symptoms Scale (NMSS) was administered at baseline (V0) and at 24 months +/- 1 month (V2). Linear regression models were used for determining predictive factors of global NMS burden progression (NMSS total score change from V0 to V2 as dependent variable). Results: After the 2-year follow-up, the mean NMS burden (NMSS total score) significantly increased in PD patients by 18.8% (from 45.08 +/- 37.62 to 53.55 +/- 42.28; p < 0.0001; N = 501; 60.2% males, mean age 62.59 +/- 8.91) compared to no change observed in controls (from 14.74 +/- 18.72 to 14.65 +/- 21.82; p = 0.428; N = 122; 49.5% males, mean age 60.99 +/- 8.32) (p < 0.0001). NMSS total score at baseline (beta = -0.52), change from V0 to V2 in PDSS (Parkinson's Disease Sleep Scale) (beta = -0.34), and change from V0 to V2 in NPI (Neuropsychiatric Inventory) (beta = 0.25) provided the highest contributions to the model (adjusted R-squared 0.41; Durbin-Watson test = 1.865). Conclusions: Global NMS burden demonstrates short-term progression in PD patients but not in controls and identifies worsening sleep problems and neuropsychiatric symptoms as significant independent predictors of this NMS progression.
Filiaciones:
Diego, SG:
Complejo Hosp Univ A Coruna, CHUAC, La Coruna 15006, Spain
Teresa, DD:
Complejo Hosp Univ Ferrol, CHUF, La Coruna 15405, Spain
Canfield, H:
Complejo Hosp Univ Ferrol, CHUF, La Coruna 15405, Spain
Paz Gonzalez, JM:
Complejo Hosp Univ A Coruna, CHUAC, La Coruna 15006, Spain
Miro, CM:
Complejo Hosp Univ A Coruna, CHUAC, La Coruna 15006, Spain
Aymerich, LV:
Complejo Hosp Univ A Coruna, CHUAC, La Coruna 15006, Spain
Suarez, E:
Complejo Hosp Univ Ferrol, CHUF, La Coruna 15405, Spain
Jesus, S:
Univ Seville, Hosp Univ Virgen Rocio, Unidad Trastornos Movimiento,CSIC, Serv Neurol & Neurofisiol Clin,Inst Biomed Sevill, Seville 41009, Spain
CIBERNED Ctr Invest Biomed Red Enfermedades Neuro, Madrid 28031, Spain
Aguilar, M:
Hosp Univ Mutua Terrassa, Barcelona 08221, Spain
Planellas, L:
Hosp Clin Barcelona, Barcelona 08036, Spain
Cosgaya, M:
Hosp Clin Barcelona, Barcelona 08036, Spain
Caldentey, JG:
Cre Neurol Oms 42, Palma De Mallorca 07003, Spain
Caballol, N:
Cre Neurol Oms 42, Palma De Mallorca 07003, Spain
Hosp Moises Broggi, Consorci Sanitari Integral, Barcelona 08970, Spain
Legarda, I:
Hosp Univ Son Espases, Palma De Mallorca 07120, Spain
Hernandez-Vara, J:
Hosp Univ Vall dHebron, Barcelona 08035, Spain
Cabo, I:
Complejo Hosp Univ Pontevedra CHOP, Pontevedra 36071, Spain
Manzanares, LL:
Hosp Univ La Princesa, Madrid 28006, Spain
Aramburu, IG:
CIBERNED Ctr Invest Biomed Red Enfermedades Neuro, Madrid 28031, Spain
Hosp Univ Marques de Valdecilla, Santander 39011, Spain
Avila Rivera, MA:
Hosp Gen LHospitalet, Consorci Sanitari Integral, Barcelona 08906, Spain
Catalan, MJ:
Hosp Univ Clin San Carlos, Madrid 28040, Spain
Nogueira, V:
Hosp Costa, Burela 27880, Spain
Puente, V:
Hosp Mar, Barcelona 08003, Spain
Dotor, J:
Hosp Univ Virgen Macarena, Seville 41009, Spain
Borrue, C:
Hosp Infanta Sofia, Madrid 28702, Spain
Solano, B:
Inst Catala Salut, Inst Assistencia Sanitaria, Girona 17190, Spain
Alvarez Sauco, M:
Hosp Gen Univ Elche, Elche 03203, Spain
Vela, L:
Fdn Hosp Alcorcon, Madrid 28922, Spain
Escalante, S:
Hosp Tortosa Verge Cinta HTVC, Tarragona 43500, Spain
Cubo, E:
Complejo Asistencial Univ Burgos, Burgos 09006, Spain
Carrillo, F:
Hosp Univ Canarias, San Cristobal Laguna 38320, Spain
Martinez Castrillo, JC:
Hosp Univ Ramon & Cajal, IRYCIS, Madrid 28034, Spain
Alonso, PS:
Hosp Univ Puerta Hierro, Madrid 28222, Spain
Alonso, G:
Complejo Hosp Univ Vigo CHUVI, Hosp Alvaro Cunqueiro, Vigo 36213, Spain
Ariztegui, NL:
Complejo Hosp Toledo, Toledo 45071, Spain
Gaston, I:
Complejo Hosp Navarra, Pamplona 31008, Spain
Kulisevsky, J:
Hosp Santa Creu & Sant Pau, Barcelona 08041, Spain
Blazquez, M:
Hosp Univ Cent Asturias, Oviedo 33011, Spain
Seijo, M:
Hosp Univ Donostia, San Sebastian 20009, Spain
Valero, C:
Hosp Arnau Vilanova, Valencia 46015, Spain
Kurtis, M:
Hosp Ruber Int, Madrid 28034, Spain
Ardura, J:
Hosp Cabuenes, Gijon 33394, Spain
Alonso, R:
Hosp Univ Lucus Augusti HULA, Lugo 27002, Spain
Ordas, C:
Hosp Rey Juan Carlos, Madrid 28933, Spain
Diaz, LML:
Complejo Hosp Univ Orense CHUO, Orense 32005, Spain
McAfee, D:
Univ Penn, Lab Cognit & Neural Stimulat, Philadelphia, PA 19104 USA
Martinez-Martin, P:
CIBERNED Ctr Invest Biomed Red Enfermedades Neuro, Madrid 28031, Spain
Mir, P:
Univ Seville, Hosp Univ Virgen Rocio, Unidad Trastornos Movimiento,CSIC, Serv Neurol & Neurofisiol Clin,Inst Biomed Sevill, Seville 41009, Spain
CIBERNED Ctr Invest Biomed Red Enfermedades Neuro, Madrid 28031, Spain
Green Published, gold
|